Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Mizuarai, Shinji ^a   Yamanaka, Kazunori ^a   Itadani, Hiraku ^a   Arai, Tsuyoshi ^a   Nishibata, Toshihide ^a   Hirai, Hiroshi ^a   Kotani, Hidehito ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALKYL 6 ANILINO 1 ARYL 1,2 DIHYDRO 3H PYRAZOLE[3,4 D]PYRIMIDIN 3 ONE; CELL CYCLE PROTEIN; CLASPIN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLIN E1; CYCLIN E2; F BOX PROTEIN; F BOX PROTEIN 5; GEMCITABINE; MINICHROMOSOME MAINTENANCE PROTEIN 5; MK 1775; PHARMACOLOGICAL BIOMARKER; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; WEE 1 KINASE; ANTINEOPLASTIC AGENT; CYCLIN B; DEOXYCYTIDINE; DRUG DERIVATIVE; NUCLEAR PROTEIN; TUMOR MARKER; WEE1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACODYNAMICS; PHARMACOGENETICS; PROTEIN FUNCTION; RAT; REGULATOR GENE; TUMOR XENOGRAFT; ANALYSIS OF VARIANCE; ANIMAL; CELL CYCLE; DNA MICROARRAY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; NUDE RAT; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; TUMOR CELL LINE;

ANIMALIA; RATTUS;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN B; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION PROFILING; HUMANS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN-TYROSINE KINASES; RATS; RATS, NUDE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649710471     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-34     Document Type: Article

References (44)

1. Yao SL Akhtar AJ McKenna KA Bedi GC Sidransky D Mabry M Ravi R Collector MI Jones RJ Sharkis SJ Fuchs EJ Bedi A Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase Nat Med 1996, 2:1140-1143 10.1038/nm1096-1140 8837615
2. Allday MJ Inman GJ Crawford DH Farrell PJ DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective EMBO J 1995, 14:4994-5005 394603 7588628
3. Zabludoff SD Deng C Grondine MR Sheehy AM Ashwell S Caleb BL Green S Haye HR Horn CL Janetka JW Liu D Mouchet E Ready S Rosenthal JL Queva C Schwartz GK Taylor KJ Tse AN Walker GE White AM AZD a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies Mol Cancer Ther 7762, 7:2955-2966 10.1158/ 1535-7163.MCT-08-0492
4. Hirao A Kong YY Matsuoka S Wakeham A Ruland J Yoshida H Liu D Elledge SJ Mak TW DNA damage-induced activation of p53 by the checkpoint kinase Chk2 Science 2000, 287:1824-1827 10.1126/science.287.5459.1824 10710310
5. Dasika GK Lin SC Zhao S Sung P Tomkinson A Lee EY DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis Oncogene 1999, 18:7883-7899 10.1038/sj.onc.1203283 10630641
6. Goi K Takagi M Iwata S Delia D Asada M Donghi R Tsunematsu Y Nakazawa S Yamamoto H Yokota J Tamura K Saeki Y Utsunomiya J Takahashi T Ueda R Ishioka C Eguchi M Kamata N Mizutani S DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation Cancer Res 1997, 57:1895-1902 9157982
7. Mizuarai S Yamanaka K Kotani H Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells Cancer Res 2006, 66:6319-6326 10.1158/ 0008-5472.CAN-05-4629 16778209
8. Lundgren K Walworth N Booher R Dembski M Kirschner M Beach D mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2 Cell 1991, 64:1111-1122 10.1016/0092-8674(91)90266-2 1706223
9. Rowley R Hudson J Young PG The wee1 protein kinase is required for radiation-induced mitotic delay Nature 1992, 356:353-355 10.1038/ 356353a0 1549179
10. Stanford JS Ruderman JV Changes in regulatory phosphorylation of Cdc25C Ser287 and Wee1 Ser549 during normal cell cycle progression and checkpoint arrests Mol Biol Cell 2005, 16:5749-5760 1289418 16195348 10.1091/mbc.E05-06-0541
11. Lee J Kumagai A Dunphy WG Positive regulation of Wee1 by Chk1 and 14-3-3 proteins Mol Biol Cell 2001, 12:551-563 30963 11251070
12. Rothblum-Oviatt CJ Ryan CE Piwnica-Worms H 14-3-3 binding regulates catalytic activity of human Wee1 kinase Cell Growth Differ 2001, 12:581-589 11751453
13. Wang Y Li J Booher RN Kraker A Lawrence T Leopold WR Sun Y Radiosensitization of p53 mutant cells by PD016 a novel G(2) checkpoint abrogator Cancer Res 6285, 61:8211-8217
14. Li J Wang Y Sun Y Lawrence TS Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD016 a WEE1 kinase inhibitor Radiat Res. 6285, 157(3):322-330 10.1667/ 0033-7587(2002)157[0322:WTTIGP]2.0.CO;2
15. Wang Y Decker SJ Sebolt-Leopold J Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis Cancer Biol Ther 2004, 3:305-313 14726685
16. Hirai H Iwasawa Y Okada M Arai T Nishibata T Kobayashi M Kimura T Kaneko N Ohtani J Sakai T Mizuarai S Yoshizumi T Hidehito Kotani Inhibition of Wee1 kinase by small molecule inhibitor enhances anti-tumor efficacy of DNA damaging agents specifically in p53-negative cancers Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009, 3732
17. Sarker D Workman P Pharmacodynamic biomarkers for molecular cancer therapeutics Adv Cancer Res 2007, 96:213-268 10.1016/ S0065-230X(06)96008-4 17161682
18. Cummings J Ward TH Greystoke A Ranson M Dive C Biomarker method validation in anticancer drug development Br J Pharmacol 2008, 153:646-656 2259203 17876307 10.1038/sj.bjp.0707441
19. Workman P Aboagye EO Chung YL Griffiths JR Hart R Leach MO Maxwell RJ McSheehy PM Price PM Zweit J Cancer Research UK Pharmacodynamic/ Pharmacokinetic Technologies Advisory Committee. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies J Natl Cancer Inst 2006, 98:580-598 16670384
20. Albanell J Rojo F Averbuch S Feyereislova A Mascaro JM Herbst R LoRusso P Rischin D Sauleda S Gee J Nicholson RI Baselga J Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition J Clin Oncol 2002, 20:110-124 10.1200/JCO.20.1.110 11773160
21. White D Saunders V Lyons AB Branford S Grigg A To LB Hughes T In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML Blood 2005, 106:2520-2526 10.1182/blood-2005-03-1103 15956284
22. Jhala N Jhala D Vickers SM Eltoum I Batra SK Manne U Eloubeidi M Jones JJ Grizzle WE Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates Am J Clin Pathol 2006, 126:572-579 10.1309/ CEV30BE088CBDQD9 17019794
23. Hardwick JS Yang Y Zhang C Shi B McFall R Koury EJ Hill SL Dai H Wasserman R Phillips RL Weinstein EJ Kohl NE Severino ME Lamb JR Sepp-Lorenzino L Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling Mol Cancer Ther 2005, 4:413-425 15767550
24. Soo RA Wu J Aggarwal A Tao Q Hsieh W Putti T Tan KB Low JS Lai YF Mow B Hsu S Loh KS Tan L Tan P Goh BC Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression Ann Oncol 2006, 17:1625-1630 10.1093/annonc/mdl283 17008411
25. Beliën A De Schepper S Floren W Janssens B Mariën A King P Van Dun J Andries L Voeten J Bijnens L Janicot M Arts J Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors Mol Cancer Ther 2006, 5:2317-2323 10.1158/ 1535-7163.MCT-06-0112 16985066
26. Bartz SR Zhang Z Burchard J Imakura M Martin M Palmieri A Needham R Guo J Gordon M Chung N Warrener P Jackson AL Carleton M Oatley M Locco L Santini F Smith T Kunapuli P Ferrer M Strulovici B Friend SH Linsley PS Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions Mol Cell Biol 2006, 26:9377-9386 1698535 17000754 10.1128/MCB.01229-06
27. Williams R Baker AF Ihle NT Winkler AR Kirkpatrick L Powis G The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling Cancer Chemother Pharmacol 2006, 58:444-450 1486800 16485116 10.1007/s00280-006-0190-0
28. Kurimoto K Yabuta Y Ohinata Y Saitou M Global single-cell cDNA amplification to provide a template for representative high-density oligonucleotide microarray analysis Nat Protoc 2007, 2:739-752 10.1038/ nprot.2007.79 17406636
29. Zheng Z Luo Y McMaster GK Sensitive and quantitative measurement of gene expression directly from a small amount of whole blood Clin Chem 2006, 52:1294-1302 10.1373/clinchem.2005.065078 16709626
30. Dowlati A Haaga J Remick SC Spiro TP Gerson SL Liu L Berger SJ Berger NA Willson JK Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation Clin Cancer Res 2001, 7:2971-2976 11595684
31. Florentine BD Cobb CJ Frankel K Greaves T Martin SE Core needle biopsy. A useful adjunct to fine-needle aspiration in select patients with palpable breast lesions Cancer 1997, 81:33-39 10.1002/ (SICI)1097-0142(19970225)81:1<33::AID-CNCR8>3.0.CO;2-H 9100539
32. Vanhoefer U Tewes M Rojo F Dirsch O Schleucher N Rosen O Tillner J Kovar A Braun AH Trarbach T Seeber S Harstrick A Baselga J Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor J Clin Oncol 2004, 22:175-184 10.1200/ JCO.2004.05.114 14701780
33. Malik SN Siu LL Rowinsky EK deGraffenried L Hammond LA Rizzo J Bacus S Brattain MG Kreisberg JI Hidalgo M Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients Clin Cancer Res 2003, 9:2478-2486 12855621
34. Chini CC Chen J Human claspin is required for replication checkpoint control J Biol Chem 2003, 278:30057-30062 10.1074/jbc.M301136200 12766152
35. Kumagai A Dunphy WG Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts Mol Cell 2000, 6:839-849 10.1016/S1097-2765(05)00092-4 11090622
36. Ricke RM Bielinsky AK Mcm10 regulates the stability and chromatin association of DNA polymerase-alpha Mol Cell 2004, 16:173-185 10.1016/ j.molcel.2004.09.017 15494305
37. Chattopadhyay S Bielinsky AK Human Mcm10 regulates the catalytic subunit of DNA polymerase-alpha and prevents DNA damage during replication Mol Biol Cell 2007, 18:4085-4095 1995709 17699597 10.1091/mbc.E06-12-1148
38. Machida YJ Dutta A The APC/C inhibitor, Emi1, is essential for prevention of rereplication Genes Dev 2007, 21:184-194 1770901 17234884 10.1101/gad.1495007
39. Moshe Y Boulaire J Pagano M Hershko A Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome Proc Natl Acad Sci USA 2004, 101:7937-7942 419535 15148369 10.1073/pnas.0402442101
40. Hinchcliffe EH Li C Thompson EA Maller JL Sluder G Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts Science 1999, 283:851-854 10.1126/science.283.5403.851 9933170
41. Dulić V Lees E Reed SI Association of human cyclin E with a periodic G1-S phase protein kinase Science 1992, 257:1958-1961 10.1126/ science.1329201 1329201
42. Saitoh M Uzuka M Sakamoto M Human hair cycle J Invest Dermatol 1970, 54:65-81 10.1111/1523-1747.ep12551679 5416680
43. Camidge DR Pemberton M Growcott J Amakye D Wilson D Swaisland H Forder C Wilkinson R Byth K Hughes A A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers Cancer Chemother Pharmacol 2007, 60:479-488 10.1007/s00280-006-0387-2 17143601
44. Murgo AJ Kummar S Rubinstein L Gutierrez M Collins J Kinders R Parchment RE Ji J Steinberg SM Yang SX Hollingshead M Chen A Helman L Wiltrout R Tomaszewski JE Doroshow JH Designing phase 0 cancer clinical trials Clin Cancer Res 2008, 14:3675-3682 10.1158/1078-0432.CCR-07-4560 18559582 2435428